Molnupiravir市場-行業規模,份額,趨勢,機會,預測,2017-2027,按應用,分銷渠道(醫院藥房,零售,線上藥房),地區
市場調查報告書
商品編碼
1228260

Molnupiravir市場-行業規模,份額,趨勢,機會,預測,2017-2027,按應用,分銷渠道(醫院藥房,零售,線上藥房),地區

Molnupiravir Market-Global Industry Size, Share, Trends, Opportunity, & Forecast, 2017-2027 Segmented By Application (Influenza, Ebola, COVID-19, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region

出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

在 2023 年至 2027 年的預測期內,由於 COVID-19 病例數量不斷增加,對有效藥物的需求不斷增長,因此 molnupiravir 的全球市場可能會出現令人矚目的增長。

全球 molnupiravir 市場在未來 5 年內增長,原因是該疾病的高流行率和病毒變異使患者的病情複雜化,導致嚴重的感染狀況並導致人們死亡。促進它。 此外,各種製藥和生物技術公司為開發潛在的抗病毒藥物而增加的研發活動預計將推動市場增長。

越來越多的 COVID-19 病例推動了市場增長

COVID-19 陽性病例數量的增加將是未來五年推動全球 molnupiravir 市場增長的關鍵因素。 有效的免疫接種和預防措施減緩了病例激增的速度。 然而,越來越多的病毒亞種和對人體的影響越來越大,增加了對 molnupiravir 等高效藥物的需求,推動了未來五年全球 molnupiravir 市場的增長。

截至 2022 年 5 月 24 日,全球有 5.2837 億 CVID-19 患者,其中 8511 萬在美國。 由於在美國有如此多的人被感染,美國政府急於允許將 mornupiravir 用於患有輕度 COVID-19 症狀的患者。 當這種口服膠囊首次上市時,人們擔心會出現副作用。 從那時起,該藥物的行業因其相對於其他療法的可承受性而不斷擴大,並且已經批准的 III 期人體試驗導致該藥物在預測期內顯著增長。

市場進一步增長的投資和進展

製藥行業不斷增加的投資以及消費者在有效藥物開發和抗病方面的支出不斷增加,將在未來五年內推動全球 molnupiravir 市場的增長。 消費者渴望適應更先進、高效的藥物。 如果這些藥物在當地醫藥市場上價格合理且可用,更高效的分銷渠道將在未來五年內進一步加速全球 molnupiravir 市場的增長。

2021 年,在獲得美國食品和藥物管理局的緊急使用授權後,大約七週內向美國政府提供了超過 300 萬療程的 molnupiravir。 由於北美地區傳染病爆發的次數不斷增加,對藥品的需求很高。 其他藥物的進一步發展和創新 COVID-19 限制性藥物的進步可能是抑制市場增長的因素。

可自定義

TechSci Research 根據市場數據為公司的特定需求提供定制服務。 該報告可以定制為:

公司資訊

  • 對其他市場參與者(最多 5 家公司)進行深入分析和概況分析。

內容

第 1 章概述

第 2 章研究方法論

第 3 章 COVID-19 對全球 Mornupiravir 市場的影響

第 4 章執行摘要

第 5 章客戶反饋

  • 影響 molnupiravir 需求的因素
  • molnupiravir 來源的選擇
  • 從哪裡獲取資訊
  • 阻礙 molnupiravir 傳播的因素
  • 品牌知名度

第 6 章 Mornupiravir 藥理學概述

  • 作用機制
  • 吸收
  • 分佈量
  • 蛋白質結合
  • 新陳代謝
  • 排泄途徑
  • 半衰期
  • 清關

第 7 章臨床試驗

  • 正在進行的臨床試驗
  • 完成臨床試驗
  • 完成臨床試驗
  • 臨床試驗分析

第 8 章專利分析

  • 專利狀態(2017-2021 年)
  • 已申請專利

第 9 章 Mornupiravir 的全球市場展望

  • 市場規模和預測
    • 按金額/數量
  • 市場份額和預測
    • 按應用(流感、埃博拉、COVID-19 等)
    • 按分銷渠道(住院藥房、零售藥房、在線藥房)
    • 按公司分類(2021 年)
    • 按地區
  • 價格分析
  • 產品市場地圖

第 10 章 Mornupiravir 在北美的市場展望

  • 市場規模和預測
    • 按金額/數量
  • 市場份額/預測
    • 通過申請
    • 按分銷渠道
    • 按國家
  • 價格分析
  • 北美分析
    • 美國
    • 墨西哥
    • 加拿大

第 11 章歐洲 Mornupiravir 的市場展望

  • 市場規模和預測
    • 按金額/數量
  • 市場份額/預測
    • 通過申請
    • 按分銷渠道
    • 按國家
  • 價格分析
  • 歐洲國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙
    • 丹麥

第 12 章亞太地區 Mornupiravir 市場展望

  • 市場規模和預測
    • 按金額/數量
  • 市場份額和預測
    • 通過申請
    • 按分銷渠道
    • 按國家
  • 價格分析
  • 亞太國家/地區分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳大利亞
    • 越南
    • 菲律賓
    • 印度尼西亞
    • 馬來西亞

第 13 章:南美洲 Mornupiravir 市場展望

  • 市場規模和預測
    • 按金額/數量
  • 市場份額/預測
    • 通過申請
    • 按分銷渠道
    • 按國家
  • 價格分析
  • 南美洲國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 14 章中東和非洲的 Mornupiravir 市場展望

  • 市場規模和預測
    • 按金額/數量
  • 市場份額/預測
    • 通過申請
    • 按分銷渠道
    • 按國家
  • 價格分析
  • MEA:國家分析
    • 南非的 Molnupiravir
    • 沙特阿拉伯的 Molnupiravir
    • 阿聯酋的 Molnupiravir
    • 肯尼亞的 Molnupiravir

第 15 章市場動態

  • 促進因素
  • 任務

第 16 章新興市場的市場趨勢與發展

第 17 章市場趨勢競爭態勢

  • 公司概況
    • 公司詳情
    • 財務資訊(合併基礎)
    • 主要市場焦點和地域分佈
    • 符合條件的產品定價
    • 市場定位
  • Merck Sharp & Dohme Corp.
  • Everest Organics Limited
  • Optimus Drugs Pvt Ltd.
  • Dr. Reddy's Laboratories Ltd
  • Cipla Limited
  • Mylan N.V.
  • Emcure Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Limited
  • Hetero Drugs Ltd.
  • Torrent Pharmaceuticals Ltd.

第 18 章戰略建議

簡介目錄
Product Code: 10604

Global Molnupiravir market may register impressive growth in the forecast period, 2023-2027, due to rising demands for effective pharmaceuticals for the rising cases of COVID-19. The high prevalence of the disease coupled with the viral variant complicates the conditions of the patients and thus leading to severe conditions of the infection and causing death for the population, driving the growth of the global Molnupiravir market in the upcoming five years. Furthermore, increasing research and development activities by various pharmaceutical & biotechnology players for the development of potential antiviral drugs is anticipated to foster market growth.

Molnupiravir is an orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV2, the causative agent of COVID-19. In simpler terms, the pharmaceutical product Molnupiravir is an orally administered drug that has higher potency as compared to other antiviral drugs against COVID-19. The drug has the chemical composition of mRNA that can act against the viral, and COVID infection-causing virus' RNA. This RNA sequence has an effect against the new SARS-CoV2 too is thus used for controlling the effects of COVID-19.

Rising Instances of COVID-19 Drives Market Growth

Growing instances of COVID-19-positive cases are a major factor driving the growth of the global Molnupiravir market in the upcoming five years. Although through effective vaccinations and the use of precautionary steps, the rapid growth in the cases has been controlled. Although, growing variants of the virus and its evolving effect on the human body affect lives, and thus the demand for efficient pharmaceuticals such as Molnupiravir increases thereby supporting the growth of the global Molnupiravir market in the next five years.

As of 24th May 2022, there are already 528.37 million CVID-19 cases around the world, out of which 85.11 million cases belong to the United States itself. With the viral infection affecting such a large population in the country, the United States government had hastily authorized the administration of Molnupiravir to patients suffering from the mild symptoms of COVID-19. The orally administered capsules had certain concerns and side effects in their early phase-outs. Soon followed by the affordability of the drug as compared to other available treatment drugs, the industry for the drug expanded and with Clinical Phase III human trials already approved, the drug is expected to substantially grow in the forecast years.

Investments & Advancement Wheel In Further Market Growth

Rising investment in the pharmaceutical industry and growing expenses from the consumers toward effective drug development and overcoming the disease drives the growth of the global Molnupiravir market in the upcoming five years. Consumers are eager to adapt to more advanced, highly effective, and efficient drugs. If these drugs are affordable and are available in the local pharmaceutical markets, the distribution channel efficiency further fuels the growth of the global Molnupiravir market in the next five years.

In 2021, more than 3 million courses of Molnupiravir were supplied to the U.S. government within approximately 7 weeks of receiving emergency use authorization from the U.S. food and drug administration. The demands for drugs are high in the North American region looking at the growing instances of the cases in the country. Further evolutions in other pharmaceuticals and advancements in the innovative COVID-19 restricting drugs may create restraint on the growth of the market.

Market Segmentation

The global Molnupiravir market segmentation is based on application, distribution channel, regional distribution, and competitive landscape. Based on application, the market is fragmented into influenza, Ebola, COVID-19, and others. By distribution channel, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The market analysis also studies the regional segmentation, divided among the Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Merck Sharp & Dohme Corp., Everest Organics Limited, Optimus Drugs Pvt Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Mylan N.V., Emcure Pharmaceuticals Ltd., Sun Pharmaceutical Industries Limited, Hetero Drugs Ltd., Torrent Pharmaceuticals Ltd., are enlisted in a partial list of major market players of the global Molnupiravir market.

Report Scope

In this report, global Molnupiravir market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molnupiravir Market, By Type:

  • Influenza
  • Ebola
  • COVID-19
  • Others

Molnupiravir Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Molnupiravir Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Vietnam
    • Philippines
    • Indonesia
    • Malaysia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Spain
    • Italy
    • Denmark
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kenya

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Molnupiravir market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Molnupiravir Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Factors Contributing to Demand of Molnupiravir
  • 5.2. Choice of Source for Procuring Molnupiravir
  • 5.3. Source of Information
  • 5.4. Barriers to Adoption of Molnupiravir
  • 5.5. Brand Awareness

6. Pharmacodynamic Overview of Molnupiravir

  • 6.1. Mechanism of Action
  • 6.2. Absorption
  • 6.3. Volume of Distribution
  • 6.4. Protein Binding
  • 6.5. Metabolism
  • 6.6. Route of Elimination
  • 6.7. Half Life
  • 6.8. Clearance

7. Clinical Trials

  • 7.1. Ongoing Clinical Trials
  • 7.2. Completed Clinical Trials
  • 7.3. Terminated Clinical Trials
  • 7.4. Clinical Trial Analysis

8. Patent Analysis

  • 8.1. Patent Granted (2017-2021)
  • 8.2. Patent Applications Filed

9. Global Molnupiravir Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application (Influenza, Ebola, COVID-19, Others)
    • 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 9.2.3. By Company (2021)
    • 9.2.4. By Region
  • 9.3. Pricing Analysis
  • 9.4. Product Market Map

10. North America Molnupiravir Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. Pricing Analysis
  • 10.4. North America: Country Analysis
    • 10.4.1. United States Molnupiravir Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value & Volume
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Application
        • 10.4.1.2.2. By Distribution Channel
    • 10.4.2. Mexico Molnupiravir Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value & Volume
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Application
        • 10.4.2.2.2. By Distribution Channel
    • 10.4.3. Canada Molnupiravir Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value & Volume
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Application
        • 10.4.3.2.2. By Distribution Channel

11. Europe Molnupiravir Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Application
    • 11.2.2. By Distribution Channel
    • 11.2.3. By Country
  • 11.3. Pricing Analysis
  • 11.4. Europe: Country Analysis
    • 11.4.1. France Molnupiravir Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value & Volume
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Application
        • 11.4.1.2.2. By Distribution Channel
    • 11.4.2. Germany Molnupiravir Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value & Volume
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Application
        • 11.4.2.2.2. By Distribution Channel
    • 11.4.3. United Kingdom Molnupiravir Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value & Volume
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Application
        • 11.4.3.2.2. By Distribution Channel
    • 11.4.4. Italy Molnupiravir Market Outlook
      • 11.4.4.1. Market Size & Forecast
        • 11.4.4.1.1. By Value & Volume
      • 11.4.4.2. Market Share & Forecast
        • 11.4.4.2.1. By Application
        • 11.4.4.2.2. By Distribution Channel
    • 11.4.5. Spain Molnupiravir Market Outlook
      • 11.4.5.1. Market Size & Forecast
        • 11.4.5.1.1. By Value & Volume
      • 11.4.5.2. Market Share & Forecast
        • 11.4.5.2.1. By Application
        • 11.4.5.2.2. By Distribution Channel
    • 11.4.6. Denmark Molnupiravir Market Outlook
      • 11.4.6.1. Market Size & Forecast
        • 11.4.6.1.1. By Value & Volume
      • 11.4.6.2. Market Share & Forecast
        • 11.4.6.2.1. By Application
        • 11.4.6.2.2. By Distribution Channel

12. Asia-Pacific Molnupiravir Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Application
    • 12.2.2. By Distribution Channel
    • 12.2.3. By Country
  • 12.3. Pricing Analysis
  • 12.4. Asia-Pacific: Country Analysis
    • 12.4.1. China Molnupiravir Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value & Volume
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Application
        • 12.4.1.2.2. By Distribution Channel
    • 12.4.2. India Molnupiravir Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value & Volume
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Application
        • 12.4.2.2.2. By Distribution Channel
    • 12.4.3. South Korea Molnupiravir Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value & Volume
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Application
        • 12.4.3.2.2. By Distribution Channel
    • 12.4.4. Japan Molnupiravir Market Outlook
      • 12.4.4.1. Market Size & Forecast
        • 12.4.4.1.1. By Value & Volume
      • 12.4.4.2. Market Share & Forecast
        • 12.4.4.2.1. By Application
        • 12.4.4.2.2. By Distribution Channel
    • 12.4.5. Australia Molnupiravir Market Outlook
      • 12.4.5.1. Market Size & Forecast
        • 12.4.5.1.1. By Value & Volume
      • 12.4.5.2. Market Share & Forecast
        • 12.4.5.2.1. By Application
        • 12.4.5.2.2. By Distribution Channel
    • 12.4.6. Vietnam Molnupiravir Market Outlook
      • 12.4.6.1. Market Size & Forecast
        • 12.4.6.1.1. By Value & Volume
      • 12.4.6.2. Market Share & Forecast
        • 12.4.6.2.1. By Application
        • 12.4.6.2.2. By Distribution Channel
    • 12.4.7. Philippines Molnupiravir Market Outlook
      • 12.4.7.1. Market Size & Forecast
        • 12.4.7.1.1. By Value & Volume
      • 12.4.7.2. Market Share & Forecast
        • 12.4.7.2.1. By Application
        • 12.4.7.2.2. By Distribution Channel
    • 12.4.8. Indonesia Molnupiravir Market Outlook
      • 12.4.8.1. Market Size & Forecast
        • 12.4.8.1.1. By Value & Volume
      • 12.4.8.2. Market Share & Forecast
        • 12.4.8.2.1. By Application
        • 12.4.8.2.2. By Distribution Channel
    • 12.4.9. Malaysia Molnupiravir Market Outlook
      • 12.4.9.1. Market Size & Forecast
        • 12.4.9.1.1. By Value & Volume
      • 12.4.9.2. Market Share & Forecast
        • 12.4.9.2.1. By Application
        • 12.4.9.2.2. By Distribution Channel

13. South America Molnupiravir Market Outlook

  • 13.1. Market Size & Forecast
    • 13.1.1. By Value & Volume
  • 13.2. Market Share & Forecast
    • 13.2.1. By Application
    • 13.2.2. By Distribution Channel
    • 13.2.3. By Country
  • 13.3. Pricing Analysis
  • 13.4. South America: Country Analysis
    • 13.4.1. Brazil Molnupiravir Market Outlook
      • 13.4.1.1. Market Size & Forecast
        • 13.4.1.1.1. By Value & Volume
      • 13.4.1.2. Market Share & Forecast
        • 13.4.1.2.1. By Application
        • 13.4.1.2.2. By Distribution Channel
    • 13.4.2. Argentina Molnupiravir Market Outlook
      • 13.4.2.1. Market Size & Forecast
        • 13.4.2.1.1. By Value & Volume
      • 13.4.2.2. Market Share & Forecast
        • 13.4.2.2.1. By Application
        • 13.4.2.2.2. By Distribution Channel
    • 13.4.3. Colombia Molnupiravir Market Outlook
      • 13.4.3.1. Market Size & Forecast
        • 13.4.3.1.1. By Value & Volume
      • 13.4.3.2. Market Share & Forecast
        • 13.4.3.2.1. By Application
        • 13.4.3.2.2. By Distribution Channel

14. Middle East and Africa Molnupiravir Market Outlook

  • 14.1. Market Size & Forecast
    • 14.1.1. By Value & Volume
  • 14.2. Market Share & Forecast
    • 14.2.1. By Application
    • 14.2.2. By Distribution Channel
    • 14.2.3. By Country
  • 14.3. Pricing Analysis
  • 14.4. MEA: Country Analysis
    • 14.4.1. South Africa Molnupiravir Market Outlook
      • 14.4.1.1. Market Size & Forecast
        • 14.4.1.1.1. By Value & Volume
      • 14.4.1.2. Market Share & Forecast
        • 14.4.1.2.1. By Application
        • 14.4.1.2.2. By Distribution Channel
    • 14.4.2. Saudi Arabia Molnupiravir Market Outlook
      • 14.4.2.1. Market Size & Forecast
        • 14.4.2.1.1. By Value & Volume
      • 14.4.2.2. Market Share & Forecast
        • 14.4.2.2.1. By Application
        • 14.4.2.2.2. By Distribution Channel
    • 14.4.3. UAE Molnupiravir Market Outlook
      • 14.4.3.1. Market Size & Forecast
        • 14.4.3.1.1. By Value & Volume
      • 14.4.3.2. Market Share & Forecast
        • 14.4.3.2.1. By Application
        • 14.4.3.2.2. By Distribution Channel
    • 14.4.4. Kenya Molnupiravir Market Outlook
      • 14.4.4.1. Market Size & Forecast
        • 14.4.4.1.1. By Value & Volume
      • 14.4.4.2. Market Share & Forecast
        • 14.4.4.2.1. By Application
        • 14.4.4.2.2. By Distribution Channel

15. Market Dynamics

  • 15.1. Drivers
  • 15.2. Challenges

16. Market Trends & Developments

17. Competitive Landscape

  • 17.1. Company Profiles
    • 17.1.1. Company Details
    • 17.1.2. Financials (As reported)
    • 17.1.3. Key Market Focus and Geographical Presence
    • 17.1.4. Pricing of Target Products
    • 17.1.5. Market positioning
  • 17.2. Merck Sharp & Dohme Corp.
  • 17.3. Everest Organics Limited
  • 17.4. Optimus Drugs Pvt Ltd.
  • 17.5. Dr. Reddy's Laboratories Ltd
  • 17.6. Cipla Limited
  • 17.7. Mylan N.V.
  • 17.8. Emcure Pharmaceuticals Ltd.
  • 17.9. Sun Pharmaceutical Industries Limited
  • 17.10. Hetero Drugs Ltd.
  • 17.11. Torrent Pharmaceuticals Ltd.

18. Strategic Recommendations